Merck (MRK) Other Gross PP&E Adjustments (2009 - 2025)
Merck (MRK) reported Other Gross PP&E Adjustments of -$1.2 billion for Q4 2025, down 11.57% year-over-year from -$1.3 billion in Q4 2024, and down 11.57% quarter-over-quarter from -$1.1 billion in Q4 2024.
Merck (MRK) Other Gross PP&E Adjustments (2009 - 2025) Analysis & Trends
Merck (MRK) has 17 years of Other Gross PP&E Adjustments data on file, last reported at -$1.2 billion in Q4 2025.
- Other Gross PP&E Adjustments for Q4 2025 came in at -$1.2 billion, down 11.57% year-over-year; the trailing twelve-month figure through Dec 2025 was -$1.2 billion (down 11.57% YoY), and the FY2025 annual result was -$1.2 billion, down 11.57% from the prior year.
- Other Gross PP&E Adjustments eased to -$1.2 billion in Q4 2025 per MRK's latest filing, from -$1.1 billion in the prior quarter.
- Over five years, Other Gross PP&E Adjustments peaked at -$1.1 billion in Q4 2022 and troughed at -$1.3 billion in Q4 2021.
- A 5-year average of -$1.1 billion and a median of -$1.1 billion in 2023 frame the typical range for Other Gross PP&E Adjustments.
- The sharpest annual moves came in 2022 and 2025: Other Gross PP&E Adjustments rose 16.59% in 2022, then fell 11.57% in 2025.
- A 5-year view of Other Gross PP&E Adjustments shows it stood at -$1.3 billion in 2021, then climbed by 16.59% to -$1.1 billion in 2022, then decreased by 5.71% to -$1.1 billion in 2023, then increased by 4.32% to -$1.1 billion in 2024, then slipped by 11.57% to -$1.2 billion in 2025.
- Business Quant data shows MRK's Other Gross PP&E Adjustments at -$1.2 billion in Q4 2025, -$1.1 billion in Q4 2024, and -$1.1 billion in Q4 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Gross PP&E Adjustments (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 96,436,181.12 Bn | 96,436,176.16 Bn | 7.76 Bn | -941.03 Mn |
| 2 | Eli Lilly | 1,017.30 Bn | 1,012.01 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 579.61 Bn | 557.55 Bn | 15.96 Bn | 49.60 Bn |
| 4 | AbbVie | 402.30 Bn | 392.96 Bn | 10.78 Bn | - |
| 5 | Merck | 294.24 Bn | 288.59 Bn | 12.09 Bn | - |
| 6 | Amgen | 191.82 Bn | 179.78 Bn | 5.87 Bn | -2.70 Bn |
| 7 | Gilead Sciences | 155.93 Bn | 148.21 Bn | 5.52 Bn | 8.42 Bn |
| 8 | Pfizer | 149.05 Bn | 136.28 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 116.33 Bn | 105.88 Bn | 8.07 Bn | -1.53 Bn |
| 10 | Novartis Ag | 112.59 Bn | 111.90 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -1.19 Bn |
| Dec 31, 2025 | -1.19 Bn |
| Dec 31, 2024 | -1.06 Bn |
| Dec 31, 2024 | -1.06 Bn |
| Dec 31, 2023 | -1.11 Bn |
| Dec 31, 2023 | -1.11 Bn |
| Dec 31, 2022 | -1.05 Bn |
| Dec 31, 2022 | -1.05 Bn |
| Dec 31, 2021 | -1.26 Bn |
| Dec 31, 2021 | -1.26 Bn |
| Dec 31, 2020 | -1.35 Bn |
| Dec 31, 2020 | -1.35 Bn |
| Dec 31, 2019 | -730.00 Mn |
| Dec 31, 2019 | -730.00 Mn |
| Sep 30, 2019 | -1.09 Bn |
| Sep 30, 2019 | -1.09 Bn |
| Jun 30, 2019 | -1.06 Bn |
| Jun 30, 2019 | -1.06 Bn |
| Mar 31, 2019 | -1.10 Bn |
| Mar 31, 2019 | -1.10 Bn |